Use of subcutaneous Vedolizumab: A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology ( ÖGGH)

Z Gastroenterol. 2023 Nov;61(11):1518-1525. doi: 10.1055/a-2150-2156. Epub 2023 Sep 20.ABSTRACTThe humanized monoclonal anti-α4β7-integrin-antibody vedolizumab is one of several biologic therapeutic options in moderate-to-severe ulcerative colitis and Crohn's disease. Within the VISIBLE trial program, a novel subcutaneous application route was evaluated in addition to the already established intravenous form. In this position statement, the working group "Inflammatory Bowel Diseases" of the Austrian Society for Gastroenterology and Hepatology (OEGGH) summarizes the evidence regarding the subcutaneous application of vedolizumab. This work supplements a position paper on the value of vedolizumab as a first-line biologic that has already been published and offers useful recommendations for clinical practice.PMID:37944910 | DOI:10.1055/a-2150-2156

Source: Zeitschrift fur Gastroenterologie - November 9, 2023 Category: Gastroenterology Authors: Simon Reider Gottfried Novacek Thomas Haas Hans-Peter Gr öchenig Reingard Platzer Robert Koch Patrizia Katharina Kump Walter Reinisch Alexander Moschen Source Type: research